Inside Drug Pricing - 02/04/2019

Azar Says Axing Drug Rebates Makes Part B Negotiation More Attractive

By John Wilkerson
February 1, 2019 at 5:09 PM
HHS Secretary Alex Azar said Friday (Feb. 1) it would make even more sense for pharmacy benefit managers to negotiate prices for Part B drugs if rebates were eliminated. “If Congress were to move B into D, or parts of B into D, I think it makes that D option just all that more attractive,” Azar said. Subjecting Part B drugs to price negotiations in Part D used to be Azar’s top drug-pricing policy priority , and he had planned...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.